Group 1 - Company Gilead Sciences-B (01672) announced a placement and subscription agreement on August 19, 2025, involving the sale of 52.4 million shares at a price of HKD 16.45 per share [1][2] - The total number of shares being placed represents approximately 5.44% of the company's issued share capital as of the announcement date, excluding treasury shares [2] - The subscription involves the issuance of 28.82 million new shares, which accounts for about 2.90% of the enlarged share capital post-placement and subscription [2] Group 2 - The placement price of HKD 16.45 per share reflects a discount of approximately 9.9% compared to the closing price of HKD 18.26 on August 18, 2025 [2] - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from approximately 53.38% to 49.45% of the issued share capital, excluding treasury shares [2] - The net proceeds from the subscription are expected to be around HKD 468 million, with about 90% allocated for clinical trial development related to obesity treatments and 10% for general corporate purposes [2]

Core Viewpoint - The company, Gilead Sciences-B (01672), has entered into a placement and subscription agreement to sell and issue shares, which will result in a significant change in shareholding structure and raise funds for clinical trials and operational needs [1][2]. Group 1: Share Placement and Subscription Details - The total number of shares to be placed is 52.4 million, representing approximately 5.44% of the company's issued share capital as of the announcement date [2]. - The subscription involves 28.82 million new shares, accounting for about 2.90% of the enlarged issued share capital post-placement and subscription [2]. - The placement price is set at HKD 16.45 per share, which is a discount of approximately 9.9% compared to the closing price of HKD 18.26 on the last trading day [2]. Group 2: Shareholding Changes - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from approximately 53.38% to 49.45% of the issued share capital [2]. - The total shareholding percentage of the controlling shareholder will reduce from about 62.21% to approximately 58.03% after the issuance of the new shares [2]. Group 3: Use of Proceeds - The net proceeds from the subscription are expected to be around HKD 468 million after deducting commissions and estimated expenses [2]. - Approximately 90% of the net proceeds is intended for the development of clinical trials related to subcutaneous and oral peptide candidates for obesity [2]. - The remaining 10% of the net proceeds is suggested for working capital and other general corporate purposes [2].

Core Viewpoint - The company, Gilead Sciences, announced a placement and subscription agreement for the sale of 52,400,000 shares at a price of HKD 16.45 per share, representing a discount of approximately 9.9% from the last closing price of HKD 18.26 on August 18 [1] Group 1 - The net proceeds from the subscription are expected to be approximately HKD 467.69 million after deducting commissions and estimated expenses [1] - Approximately 90% of the net proceeds is intended for the clinical trial development of subcutaneous and oral peptide candidates related to obesity [1] - About 10% of the net proceeds is suggested to be used for working capital and other general corporate purposes [1]

Core Viewpoint - The company, Gilead Sciences (stock code: 1672), announced a financing plan through the placement of existing shares and the issuance of new shares, raising approximately HKD 470 million for clinical trials and operational needs [1] Group 1: Financing Details - The company plans to place 52,400,000 existing shares and issue 28,820,000 new shares at a price of HKD 16.45 per share, representing a discount of about 9.9% compared to the closing price of HKD 18.26 on August 18, 2025 [1] - The placement of existing shares accounts for approximately 5.44% of the current issued share capital, while the new shares will represent about 2.99% of the existing share capital [1] - The funds raised will be allocated with approximately HKD 420 million for clinical trials related to subcutaneous and oral peptide candidates for obesity, and about HKD 50 million for working capital and other general corporate purposes [1] Group 2: Regulatory and Completion Aspects - The issuance is conducted under a general mandate granted by the shareholders' meeting, and the subscription will be completed upon meeting relevant conditions, but no later than 14 days after August 19, 2025 [1]

Group 1 - Company Gilead Sciences-B (01672.HK) announced a placement and subscription agreement involving the sale of 52.4 million shares at a price of HKD 16.45 per share, which represents a discount of approximately 9.9% compared to the closing price of HKD 18.26 on August 18 [1] - The total number of shares being placed represents about 5.44% of the company's issued share capital, while the subscription of 28.82 million shares accounts for approximately 2.90% of the enlarged issued share capital [1] - Following the completion of the placement and subscription, the controlling shareholder's stake will decrease from approximately 62.21% to about 58.03% of the issued share capital [2] Group 2 - The total expected proceeds from the subscription amount to approximately HKD 474 million, with a net amount of about HKD 468 million after deducting commissions and estimated expenses [2] - Approximately 90% of the net proceeds from the subscription are intended for clinical trial development related to subcutaneous and oral peptide candidates for obesity, while about 10% is suggested for working capital and other general corporate purposes [2]

Core Viewpoint - The company, Geely Pharmaceutical, announced a placement and subscription agreement to sell 52,400,000 shares at a price of HKD 16.45 per share, representing a discount of approximately 9.9% from the last closing price of HKD 18.26 on August 18, 2023 [1] Group 1 - The net proceeds from the subscription are expected to be approximately HKD 467.69 million after deducting commissions and estimated expenses [1] - Approximately 90% of the net proceeds is intended for the clinical trial development of subcutaneous and oral peptide candidates related to obesity [1] - About 10% of the net proceeds is suggested to be used for working capital and other general corporate purposes [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售證券的要約或招攬購買或認購證券的任何要約。除非已根據一九三三年美國證券法（經修訂） 登記或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開發售將 僅以招股章程的方式進行，該招股章程可向證券發行人或賣方取得，並載有發行人及管理層的 詳細資料以及財務資料。本公司無意於美國公開發售本公告所述證券。 Ascletis Pharma Inc. 歌禮製藥有限公司 （ 於開曼群島註冊成立的有限公司 ） （股份代號：1672） (1)根據一般授權配售現有股份及補足認購新股份 及 (2)補足賣方股份出售 獨家整體協調人及獨家配售代理 由於配售及認購的完 ...

Core Viewpoint - The stock price of Gilead Sciences-B (01672) has increased over 3%, with a cumulative rise of over 100% in the past month, reflecting strong market performance and positive developments in its drug pipeline [1] Financial Performance - For the six months ending June 30, 2025, the company reported total revenue of RMB 104 million, representing a year-on-year increase of 111.4% [1] - Research and development costs amounted to RMB 147 million, showing a year-on-year increase of 10.9% [1] - The loss attributable to equity shareholders was RMB 87.95 million, a reduction of 32.5% compared to the previous year [1] - The loss per share was reported at 9.14 cents [1] Drug Development Progress - Significant advancements were made in the metabolic disease pipeline, immune disease pipeline, and expanded indication product pipeline [1] - The ASC30 oral tablet for obesity treatment demonstrated a weight reduction of up to 6.5% after 28 days in a U.S. Phase Ib study, indicating its potential as a best-in-class candidate for obesity treatment [1] - The company initiated a U.S. Phase IIa study and rapidly enrolled 125 participants within just over a month [1] - The ASC30 subcutaneous injection, administered once monthly or less frequently, showed a half-life of 36 days in obesity patients during a U.S. Phase Ib study, supporting its potential for less frequent dosing [1]

智通财经APP获悉，歌礼制药-B(01672)涨超3%，近一个月股价累计涨幅超1倍。截至发稿，涨3.49%， 报18.36港元，成交额1.42亿港元。 消息面上，8月15日，歌礼制药-B发布截至2025年6月30日止6个月的中期业绩，该集团取得收入总额人 民币1.04亿元(单位下同)，同比增加111.4%；研发成本1.47亿元，同比增加10.9%；公司权益股东应占亏 损8795.1万元，同比减少32.5%；每股亏损9.14分。 本集团开展美国IIa期研究并于仅一月余内迅速完成125名受试者入组；ASC30每月一次或更低频次皮下 注射治疗肥胖症：在美国Ib期研究中，单次皮下注射后在肥胖症患者中表现出36天半衰期，支持每月一 次或更低频次给药。 于报告期内及直至本公告日期，本集团在代谢性疾病管线、免疫性疾病管线及拓展性适应症产品管线方 面取得重大进展：ASC30每日一次口服片治疗肥胖症：在美国Ib期研究中，经28天治疗后，经安慰剂校 准后的相对基线的平均体重下降高达6.5%，证明其有望成为治疗肥胖症的同类最佳候选药物。 ...

Core Insights - The company announced promising preclinical efficacy results for its obesity treatment candidate ASC47 in combination with the dual-target peptide ASC31 [1][2] - ASC31 is a novel GLP-1R and GIPR dual-target agonist peptide developed by the company, showing favorable pharmacokinetic characteristics and positive in vivo efficacy in DIO mice [1][2] - ASC47 is a selective small molecule agonist of thyroid hormone receptor β (THRβ) designed for monthly subcutaneous injection, targeting fat tissue to achieve high drug concentrations [1] Clinical Study Results - A study comparing low-dose ASC47 (9 mg/kg, subcutaneous) combined with ASC31 (3 nmol/kg, subcutaneous) versus ASC47 combined with terzepatide (3 nmol/kg, subcutaneous) over 14 days showed that the ASC47 and ASC31 combination resulted in an average weight loss of 44.8%, which is 17.6% more than the ASC47 and terzepatide combination (38.1%) [2] - The CEO highlighted the significant differentiation potential of the new therapy compared to existing weight loss drugs and other candidates in development, indicating a robust pipeline for obesity treatments that includes both small molecules and peptides [2]